Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07637942 · ClinicalTrials.gov registry record
Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
A clinical trial, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- Not yet
- Registry status
- 40
- Enrollment target
NCT07637942: Clinical Trial study, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
NCT07637942 is a clinical trial that has not yet begun recruiting, run by International Maternal Pediatric Adolescent AIDS Clinical Trials Group. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07637942 has not yet begun recruiting, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- NOT YET RECRUITING
- Registry status
- 40 participants
- Enrollment target
Study Summary
Phase IV, multi-site, open-label, non-randomized study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) during pregnancy and postpartum.
Primary Outcome
Population PK: geometric mean clearance of CAB and RPV in second trimester, third trimester, and postpartum derived from a population PK model
Interventions
- DRUG Every 4-week long-acting injectable cabotegravir and rilpivirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2028-02-15 |
What is known before NCT07637942 opens enrollment
NCT07637942 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Every 4-week long-acting injectable cabotegravir and rilpivirine is the first listed.
NCT07637942 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07637942 about?
NCT07637942 is a clinical study titled "Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy". Phase IV, multi-site, open-label, non-randomized study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) during pregnancy and postpartum.
What is the current status of trial NCT07637942?
This trial is currently not yet recruiting. The enrollment target is 40 participants. The study started on 2026-07-15. Estimated completion is 2028-02-15.
What interventions are being tested in trial NCT07637942?
The interventions under investigation include: Every 4-week long-acting injectable cabotegravir and rilpivirine (DRUG).
Who is sponsoring clinical trial NCT07637942?
This trial is sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI